Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Experts discuss the clinical implications of the MAJIC-PV trial.

Panel experts comment on the role of transplant in patients with myelofibrosis.

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Faculty offer insights into the future of PV management as well as unmet needs.

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.